Marinus Pharmaceuticals Provides Business Update and 2017 Financial Results
Marinus Pharmaceuticals, Inc. (MRNS)
Last marinus pharmaceuticals, inc. earnings: 11/6 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.marinuspharma.com/investor-relations
Company Research
Source: GlobeNewswire
RADNOR, Pa., March 06, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its clinical development activities and reported its financial results for the year ended December 31, 2017. Near-term Clinical Value Catalysts Initiate Phase 3 pivotal study with oral ganaxolone in children with CDD (CDKL5 Deficiency Disorder) mid-2018Report top-line intravenous (IV) ganaxolone data from Phase 2 Magnolia study in women with severe postpartum depression (PPD) third quarter 2018.Report top-line oral ganaxolone data from Amaryllis study in women with moderate PPD fourth quarter 2018. “2017 was a significant year for Marinus, and one that has positioned us for important data readouts and advancing ganaxolone into late stage development in 2018,” said Christopher M. Cashman, chief executive offic
Show less
Read more
Impact Snapshot
Event Time:
MRNS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRNS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRNS alerts
High impacting Marinus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
MRNS
News
- Levi & Korsinsky Investigates Possible Securities Fraud Violations by Marinus Pharmaceuticals, Inc. (MRNS)Accesswire
- INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Marinus Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire
- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its price target lowered by analysts at Truist Financial Co. from $25.00 to $10.00. They now have a "buy" rating on the stock.MarketBeat
- Lost Money on Marinus Pharmaceuticals, Inc.(MRNS)? Contact Levi & Korsinsky Regarding an Ongoing InvestigationAccesswire
- Marinus (MRNS) Down 83% on Lead Drug Falling Short in Seizure Study [Yahoo! Finance]Yahoo! Finance
MRNS
Earnings
- 3/5/24 - Miss
MRNS
Sec Filings
- 4/19/24 - Form SC
- 4/4/24 - Form DEFA14A
- 4/4/24 - Form DEF
- MRNS's page on the SEC website